Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Mesenchymal Precursor/Stem Cells from Bone Marrow Stroma in Spinal Cord...
share announcement

Mesenchymal Precursor/Stem Cells from Bone Marrow Stroma in Spinal Cord Repair

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Nervous System".

Deadline for manuscript submissions: closed (20 July 2021) | Viewed by 13635

Special Issue Editor

Dr. Stuart Hodgetts

E-Mail Website1 Website2
Guest Editor
The University of Western Australia, and the Perron Institute for Neurological and Translational Science, Perth, Australia
Interests: spinal cord stem cell transplantation; gene therapy (local and cortical to induce plasticity); in vivo reprogramming; tissue engineering (scaffolds and self-assembling peptides); neuroprotection; immunomodulation; non-invasive therapies (red/near infra-red light and repetitive transcranial magnetic stimulation); “cellF”

Special Issue Information

Dear Colleagues,

Traumatic spinal cord injury (SCI) results in the disconnection of ascending motor and descending sensory pathways, resulting in paralysis below the lesion, sensory loss and disruption of autonomic systems. Mesenchymal precursor/stem cells (MPCs/MSCs) from bone marrow are considered a highly promising tested transplantation candidate to limit tissue loss and promote morphological and functional repair after SCI. Their mode of action is thought to include neuroprotection, modulation of the secondary injury cascades and immune response, transdifferentiation, reducing demyelination and promoting axonal regeneration and/or sprouting. The resulting altered local environment of the cell-transplanted SCI site provides an improved platform for tissue sparing and the regrowth of axons. These cells also show properties of homing toward the lesion if introduced systemically. Combinations of other strategies with MPC/MSC transplants offer encouraging enhanced synergistic effects. Yet disparity exists between preclinal studies in animal models and clinical outcomes in SCI patients.

The aim of this Special Issue is to highlight the many facets of MPC/MSC use in preclinical models to optimise outcomes after different types of SCI that remain to be fully elucidated, including; secretome, exosomes, timing of delivery, location (whether local vs systemic), repeated delivery, combination therapies, and the heterogeneity of growth outcomes in sensory vs motor pathways.

Dr. Stuart Hodgetts
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MPC/MSC transplantation
  • combined therapies
  • regeneration
  • regrowth
  • tissue-engineered scaffolds
  • self-assembling peptides
  • neuroprotection
  • immunomodulation
  • secretome
  • exosomes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 11219 KiB  
Article
The Effect of Inflammatory Priming on the Therapeutic Potential of Mesenchymal Stromal Cells for Spinal Cord Repair
by Inés Maldonado-Lasunción, Agnes E. Haggerty, Akinori Okuda, Tokumitsu Mihara, Natalia de la Oliva, Joost Verhaagen and Martin Oudega
Cells 2021, 10(6), 1316; https://doi.org/10.3390/cells10061316 - 25 May 2021
Cited by 11 | Viewed by 3997
Abstract
Mesenchymal stromal cells (MSC) are used for cell therapy for spinal cord injury (SCI) because of their ability to support tissue repair by paracrine signaling. Preclinical and clinical research testing MSC transplants for SCI have revealed limited success, which warrants the exploration of [...] Read more.
Mesenchymal stromal cells (MSC) are used for cell therapy for spinal cord injury (SCI) because of their ability to support tissue repair by paracrine signaling. Preclinical and clinical research testing MSC transplants for SCI have revealed limited success, which warrants the exploration of strategies to improve their therapeutic efficacy. MSC are sensitive to the microenvironment and their secretome can be altered in vitro by exposure to different culture media. Priming MSC with inflammatory stimuli increases the expression and secretion of reparative molecules. We studied the effect of macrophage-derived inflammation priming on MSC transplants and of primed MSC (pMSC) acute transplants (3 days) on spinal cord repair using an adult rat model of moderate–severe contusive SCI. We found a decrease in long-term survival of pMSC transplants compared with unprimed MSC transplants. With a pMSC transplant, we found significantly more anti-inflammatory macrophages in the contusion at 4 weeks post transplantation (wpt). Blood vessel presence and maturation in the contusion at 1 wpt was similar in rats that received pMSC or untreated MSC. Nervous tissue sparing and functional recovery were similar across groups. Our results indicate that macrophage-derived inflammation priming does not increase the overall therapeutic potential of an MSC transplant in the adult rat contused spinal cord. Full article
(This article belongs to the Special Issue Mesenchymal Precursor/Stem Cells from Bone Marrow Stroma in Spinal Cord Repair)
►▼ Show Figures

Figure 1

Review

Jump to: Research

35 pages, 2774 KiB  
Review
Future Perspectives in Spinal Cord Repair: Brain as Saviour? TSCI with Concurrent TBI: Pathophysiological Interaction and Impact on MSC Treatment
by Paul Köhli, Ellen Otto, Denise Jahn, Marie-Jacqueline Reisener, Jessika Appelt, Adibeh Rahmani, Nima Taheri, Johannes Keller, Matthias Pumberger and Serafeim Tsitsilonis
Cells 2021, 10(11), 2955; https://doi.org/10.3390/cells10112955 - 30 Oct 2021
Cited by 7 | Viewed by 3641
Abstract
Traumatic spinal cord injury (TSCI), commonly caused by high energy trauma in young active patients, is frequently accompanied by traumatic brain injury (TBI). Although combined trauma results in inferior clinical outcomes and a higher mortality rate, the understanding of the pathophysiological interaction of [...] Read more.
Traumatic spinal cord injury (TSCI), commonly caused by high energy trauma in young active patients, is frequently accompanied by traumatic brain injury (TBI). Although combined trauma results in inferior clinical outcomes and a higher mortality rate, the understanding of the pathophysiological interaction of co-occurring TSCI and TBI remains limited. This review provides a detailed overview of the local and systemic alterations due to TSCI and TBI, which severely affect the autonomic and sensory nervous system, immune response, the blood–brain and spinal cord barrier, local perfusion, endocrine homeostasis, posttraumatic metabolism, and circadian rhythm. Because currently developed mesenchymal stem cell (MSC)-based therapeutic strategies for TSCI provide only mild benefit, this review raises awareness of the impact of TSCI–TBI interaction on TSCI pathophysiology and MSC treatment. Therefore, we propose that unravelling the underlying pathophysiology of TSCI with concomitant TBI will reveal promising pharmacological targets and therapeutic strategies for regenerative therapies, further improving MSC therapy. Full article
(This article belongs to the Special Issue Mesenchymal Precursor/Stem Cells from Bone Marrow Stroma in Spinal Cord Repair)
►▼ Show Figures

Graphical abstract

18 pages, 1962 KiB  
Review
Therapeutic Potential of Niche-Specific Mesenchymal Stromal Cells for Spinal Cord Injury Repair
by Susan L. Lindsay and Susan C. Barnett
Cells 2021, 10(4), 901; https://doi.org/10.3390/cells10040901 - 14 Apr 2021
Cited by 21 | Viewed by 5319
Abstract
The use of mesenchymal stem/stromal cells (MSCs) for transplant-mediated repair represents an important and promising therapeutic strategy after spinal cord injury (SCI). The appeal of MSCs has been fuelled by their ease of isolation, immunosuppressive properties, and low immunogenicity, alongside the large variety [...] Read more.
The use of mesenchymal stem/stromal cells (MSCs) for transplant-mediated repair represents an important and promising therapeutic strategy after spinal cord injury (SCI). The appeal of MSCs has been fuelled by their ease of isolation, immunosuppressive properties, and low immunogenicity, alongside the large variety of available tissue sources. However, despite reported similarities in vitro, MSCs sourced from distinct tissues may not have comparable biological properties in vivo. There is accumulating evidence that stemness, plasticity, immunogenicity, and adaptability of stem cells is largely controlled by tissue niche. The extrinsic impact of cellular niche for MSC repair potential is therefore important, not least because of its impact on ex vivo expansion for therapeutic purposes. It is likely certain niche-targeted MSCs are more suited for SCI transplant-mediated repair due to their intrinsic capabilities, such as inherent neurogenic properties. In addition, the various MSC anatomical locations means that differences in harvest and culture procedures can make cross-comparison of pre-clinical data difficult. Since a clinical grade MSC product is inextricably linked with its manufacture, it is imperative that cells can be made relatively easily using appropriate materials. We discuss these issues and highlight the importance of identifying the appropriate niche-specific MSC type for SCI repair. Full article
(This article belongs to the Special Issue Mesenchymal Precursor/Stem Cells from Bone Marrow Stroma in Spinal Cord Repair)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop